3 profile pacjentów, w leczeniu których wybieram metronidazol Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2023
Słowa kluczowe:
metronidazol, eradykacja Helicobacter pylori, SIBO, ostre zapalenie uchyłków
##plugins.themes.bootstrap3.article.main##
Abstrakt
W pracy przedstawiono 3 profile pacjentów z różnymi chorobami przewodu pokarmowego, u których można uzyskać korzyści z zastosowania metronidazolu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Gąsiorowska , A. (2023). 3 profile pacjentów, w leczeniu których wybieram metronidazol . Medycyna Faktów , 16(1(58), 47-50. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2755
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Malfertheiner P, Megraud F, Rokkas T et al. Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut. 2022; 71: 1724-62.
2. Shah SC, Iyer PG, Moss SF. AGA Clinical Practice update on the management of refractory Helicobacter pylori infection. Expert review. Gastroenterology. 2021; 160: 1831-41.
3. Savoldi A, Carrara E, Graham DY et al. Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in world health organization regions. Gastroenterology. 2018; 155: 1372-82.
4. Ji Y, Lu H. Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment. PLoS One. 2018; 13: 1.
5. Rezapour M, Stollman N. Diverticular disease in the elderly. Curr Gastroenterol Rep. 2019; 21: 46.
6. Pietrzak A, Bartnik W, Szczepkowski M et al. Polish interdisciplinary consensus on diagnostics and treatment of colonic diverticulosis. Pol Przegl Chir. 2015; 87: 203-20.
7. Tursi A, Scarpignato C, Strate LL et al. Colonic diverticular disease. Nat Rev Dis Primers. 2020; 6: 50.
8. Bushyhead D, Quigley EMM. Small intestinal bacterial overgrowth – pathophysiology and its implication for definition and management. Gastroenterology. 2022; 163(3): 593-607.
9. Pimentel M, Saad RJ, Long MD et al. ACG clinical guideline. Small intestinal bacterial overgrowth. Am J Gastroenterol. 2020; 115: 165-78.
10. Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017; 45: 604-16.
11. Tahan S, Melli LCFL, Mello CS et al. Effectiveness of trimethoprim-sulfamethoxazole and metronidazole in the treatment of small intestinal bacterial overgrowth in children living in a slum. J Pediatr Gastroenterol Nutr. 2013; 57: 316-8.
12. Castiglione F, Rispo A, Di Girolamo E et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn’s disease. Aliment Pharmacol Ther. 2003; 18: 1107-12.
13. Lauritano EC, Gabrielli M, Scarpellini E et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol. 2008; 103: 2031-5.
14. Marie I, Ducrotte P, Denis P et al. Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology (Oxford). 2009; 48: 1314-9.
2. Shah SC, Iyer PG, Moss SF. AGA Clinical Practice update on the management of refractory Helicobacter pylori infection. Expert review. Gastroenterology. 2021; 160: 1831-41.
3. Savoldi A, Carrara E, Graham DY et al. Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in world health organization regions. Gastroenterology. 2018; 155: 1372-82.
4. Ji Y, Lu H. Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment. PLoS One. 2018; 13: 1.
5. Rezapour M, Stollman N. Diverticular disease in the elderly. Curr Gastroenterol Rep. 2019; 21: 46.
6. Pietrzak A, Bartnik W, Szczepkowski M et al. Polish interdisciplinary consensus on diagnostics and treatment of colonic diverticulosis. Pol Przegl Chir. 2015; 87: 203-20.
7. Tursi A, Scarpignato C, Strate LL et al. Colonic diverticular disease. Nat Rev Dis Primers. 2020; 6: 50.
8. Bushyhead D, Quigley EMM. Small intestinal bacterial overgrowth – pathophysiology and its implication for definition and management. Gastroenterology. 2022; 163(3): 593-607.
9. Pimentel M, Saad RJ, Long MD et al. ACG clinical guideline. Small intestinal bacterial overgrowth. Am J Gastroenterol. 2020; 115: 165-78.
10. Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017; 45: 604-16.
11. Tahan S, Melli LCFL, Mello CS et al. Effectiveness of trimethoprim-sulfamethoxazole and metronidazole in the treatment of small intestinal bacterial overgrowth in children living in a slum. J Pediatr Gastroenterol Nutr. 2013; 57: 316-8.
12. Castiglione F, Rispo A, Di Girolamo E et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn’s disease. Aliment Pharmacol Ther. 2003; 18: 1107-12.
13. Lauritano EC, Gabrielli M, Scarpellini E et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol. 2008; 103: 2031-5.
14. Marie I, Ducrotte P, Denis P et al. Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology (Oxford). 2009; 48: 1314-9.